November 20, 2013

Use of injectable drugs for multiple sclerosis declined during the 12-month period that ended on June 30 as orally administered drugs for the condition became more popular, according to a new report.

July 17, 2013

New, abuse-deterrent formulations of two opioid painkillers have not necessarily reduced doctors' unease with prescribing them, according to a new study.

December 18, 2012

A majority of prescribers would prescribe biosimilar versions of two treatments for rheumatoid arthritis within a year of their approval, according to a new study.

June 21, 2012

Taken together, asthma and chronic obstructive pulmonary disease — which includes chronic bronchitis and emphysema — affect nearly 50 million Americans, or about 15% of the total U.S. population, according to statistics from such organizations as the Centers for Disease Control and Prevention.

February 3, 2012

Endocrinologists would prescribe a newly approved weekly treatment for Type 2 diabetes to one-fifth of their patients, a new survey showed.

December 20, 2011

The market for drugs to treat ulcerative colitis will increase from 2010's $1.7 billion to $3 billion in 2020, according to a new report by market research firm Decision Resources.

October 14, 2011

Two classes of drugs for treating Type 2 diabetes will experience the biggest growth in market share of all classes of drugs for the condition, according to a new study by Decision Resources.

September 12, 2011

It’s hard to disagree that generic drug companies have had a good run for the last several years. Branded drug companies developed a large number of drugs that proved highly effective at treating widespread medical conditions and became blockbusters, garnering billions of dollars in sales in the United States alone.

July 8, 2011

Novo Nordisk could be outpacing Eli Lilly and Amylin Pharmaceuticals in the diabetes wars, according to an analysis by healthcare market research firm Decision Resources.

February 2, 2011

Eli Lilly’s and Amylin Pharmaceuticals’ Type 2 diabetes drug, Bydureon, appears to work better at promoting weight loss than drugs made by Takeda and Merck, but it could face a challenger of its own.

December 16, 2010

An investigational treatment for irritable bowel syndrome could become a blockbuster by the end of the decade, according to a report by Decision Resources.

December 10, 2010

Biotech drugs will help drive the markets for acute and chronic gout through 2019, according to a new report by market research firm Decision Resources.

December 8, 2010

Chemotherapy drugs made by Johnson & Johnson and Merck will become the standard second-line treatment for ovarian cancer within the decade, replacing a treatment made by Bristol-Myers Squibb and generic versions, according to a new report by market research firm Decision Resources.

December 2, 2010

A growing drug-treated population will cause the Type 2 diabetes drug market in China to increase to $2.5 billion by 2014 ...

October 27, 2010

Many Type 2 diabetes patients who use the drug Onglyza (saxagliptin) switched to that drug...

October 4, 2010

The drug market for ulcerative colitis treatments will see modest growth through 2019, according to...

September 28, 2010

The drug market for Crohn's disease treatments will see moderate growth over the next decade,...

September 28, 2010

While biosimilars promise to provide therapies for a wide range of diseases, their biggest fans...

September 27, 2010

The market for hypertension drugs will drop by $3 billion by the end of the...

September 6, 2010

Biotech drugs for treating Alzheimer’s disease will more than triple the size of the market...

August 10, 2010

The drug market for unipolar depression will get smaller over the next decade due to...

July 20, 2010

Biosimilars may have cleared their biggest stretch of wilderness thanks to their inclusion in the...

June 14, 2010

An investigational drug for treating multiple sclerosis has a shot at becoming a top seller,...

June 1, 2010

Three new drugs for treating HIV from Gilead Sciences and J&J subsidiary Tibotec could have...